Pharmaceutical industry from unfair competition worried

Friday, 20.06.2008, 06:14 am (GMT)

Turkey's EU membership negotiations on the drop-down titles will create unfair competition with the pharmaceutical sector concerned, the implementation does not wish to become a member.

Intellectual Property Law on Tuesday we drop the additional protection under the certificate and that the data in the negotiation process into the future münhasiriyetinin (data exclusivity) 8 +2 +1 years to be removed, the reaction of the pharmaceutical industry has taken.

Equivalent European Medicines Association (EGA) performed by 4'üncüsü this year, "South East Europe Pharmaceutical Symposium" was held yesterday in Istanbul. Equivalent to the European integration process of the pharmaceutical industry be addressed in the symposium, particularly intellectual property rights was emphasized.

Symposium talk at the General Secretary of Turkey, Turgut Tokgöz Pharmaceuticals Employers' Unions, the EU harmonization process, the Turkish pharmaceutical industry as well as positive in terms of equivalent pharmaceutical industry will adversely affect the development, he said. Tokgöz, competition and intellectual property rights in a rational balance between the provision of a vital issue for the pharmaceutical industry is equivalent said.

EGA Director Greg Perry, the main concern in the region of the additional protection certificates, data exclusivity and patents are the bond issues, he said.